Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01521767
Other study ID # A6121196
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 2011
Est. completion date November 2011

Study information

Verified date January 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules


Description:

Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 55 Years
Eligibility Inclusion Criteria: - Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive Exclusion Criteria: - Evidence or history of clinically significant diseases

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
tolterodine tartrate
4 mg single dose of extended release capsules
tolterodine tartrate
4 mg single dose of microspheres in powder blend
tolterodine tartrate
4 mg single dose of microspheres in powder blend
tolterodine tartrate
4 mg single dose of microspheres in powder blend
tolterodine tartrate
4 mg single dose of microspheres in powder blend

Locations

Country Name City State
Singapore Pfizer Investigational Site Singapore

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of tolterodine 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Primary Maximum Observed Plasma Concentration (Cmax) of tolterodine 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of tolterodine. 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of 5-HMT 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of 5-HMT 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Maximum Observed Plasma Concentration (Cmax) of 5-HMT 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Time to Reach Maximum Observed Plasma Concentration (Tmax) of tolterodine 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Time to Reach Maximum Observed Plasma Concentration (Tmax) of 5-HMT 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Plasma Decay Half-Life (t1/2) of tolterodine 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
Secondary Plasma Decay Half-Life (t1/2) of 5-HMT 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24, 30, 36 hours post-dose
See also
  Status Clinical Trial Phase
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT05880862 - Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls Early Phase 1
Recruiting NCT04807920 - BOTOX® at the Time of Prolapse Surgery for OAB Phase 4
Terminated NCT02385500 - Fesoterodine on Urgency Episodes in Parkinson's Disease Population Phase 4
Not yet recruiting NCT02477241 - Brain Areas Involved in Bladder Filling and Contraction N/A
Completed NCT01698138 - Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Phase 4
Completed NCT00613327 - An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants Phase 4
Completed NCT00527033 - A Study of YM178 in Patients With Symptomatic Overactive Bladder Phase 2
Completed NCT00368706 - A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients Phase 3
Recruiting NCT04305743 - Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A Phase 4
Active, not recruiting NCT03681678 - Laser Therapy for Treatment of Urogenital Symptoms in Women
Completed NCT01655069 - A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 Phase 3
Completed NCT01558856 - Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder N/A
Completed NCT01157377 - Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence Phase 2
Completed NCT01381120 - Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Phase 4
Completed NCT01194999 - Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence Phase 4
Completed NCT01262391 - Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents Phase 1
Completed NCT04528784 - Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis N/A
Completed NCT02849418 - Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity Phase 3
Recruiting NCT05968885 - Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity Phase 4